Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apyx Medical (APYX) EBIT Margin (2016 - 2026)

Apyx Medical filings provide 15 years of EBIT Margin readings, the most recent being 0.06% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 2149.0% to 0.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.2%, a 2698.0% increase, with the full-year FY2025 number at 12.2%, up 2698.0% from a year prior.
  • EBIT Margin hit 0.06% in Q4 2025 for Apyx Medical, up from 6.46% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.06% in Q4 2025 to a low of 64.57% in Q1 2024.
  • Median EBIT Margin over the past 5 years was 37.37% (2021), compared with a mean of 35.41%.
  • Biggest five-year swings in EBIT Margin: surged 10753bps in 2021 and later tumbled -3699bps in 2022.
  • Apyx Medical's EBIT Margin stood at 10.06% in 2021, then plummeted by -368bps to 47.05% in 2022, then increased by 16bps to 39.39% in 2023, then soared by 46bps to 21.43% in 2024, then surged by 100bps to 0.06% in 2025.
  • The last three reported values for EBIT Margin were 0.06% (Q4 2025), 6.46% (Q3 2025), and 22.63% (Q2 2025) per Business Quant data.